NASDAQ:CBLI - Cleveland BioLabs Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.85 -0.14 (-7.04 %)
(As of 08/17/2018 04:00 PM ET)
Previous Close$1.85
Today's Range$1.85 - $1.97
52-Week Range$1.85 - $4.25
Volume27,828 shs
Average Volume16,924 shs
Market Capitalization$24.40 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.66
Cleveland BioLabs logoCleveland BioLabs, Inc., a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and Russia. Its proprietary platform of toll-like immune receptor activators (TLR) has applications in radiation mitigation, oncology immunotherapy, and vaccines. The company's product candidate is entolimod, an immune-stimulatory agent, which is used as a medical radiation countermeasure and an immunotherapy for oncology and other indications. Its development programs include CBLB612, which is in preclinical studies, a synthetic molecule that activates the toll-like heterodimeric receptor 2/6 and stimulated white blood cell generation; and that has completed Phase II for treating myelosuppressive prophylaxis in patients with breast cancer receiving doxorubicin-cyclophosphamide chemotherapy. The company is also developing Mobilan, a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. Cleveland BioLabs, Inc. has strategic partnerships with the Cleveland Clinic and Roswell Park Cancer Institute. The company was founded in 2003 and is headquartered in Buffalo, New York.

Receive CBLI News and Ratings via Email

Sign-up to receive the latest news and ratings for CBLI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CBLI
CUSIPN/A
Phone716-849-6810

Debt

Debt-to-Equity RatioN/A
Current Ratio3.86
Quick Ratio3.86

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.95 million
Price / Sales10.72
Cash FlowN/A
Price / CashN/A
Book Value$0.66 per share
Price / Book2.80

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-9,700,000.00
Net Margins-578.89%
Return on Equity-115.60%
Return on Assets-90.24%

Miscellaneous

Employees19
Outstanding Shares11,300,000
Market Cap$24.40 million

Cleveland BioLabs (NASDAQ:CBLI) Frequently Asked Questions

What is Cleveland BioLabs' stock symbol?

Cleveland BioLabs trades on the NASDAQ under the ticker symbol "CBLI."

How were Cleveland BioLabs' earnings last quarter?

Cleveland BioLabs, Inc. (NASDAQ:CBLI) announced its earnings results on Tuesday, November, 14th. The biotechnology company reported ($0.11) earnings per share for the quarter. The biotechnology company earned $0.30 million during the quarter. Cleveland BioLabs had a negative return on equity of 115.60% and a negative net margin of 578.89%. View Cleveland BioLabs' Earnings History.

When is Cleveland BioLabs' next earnings date?

Cleveland BioLabs is scheduled to release their next quarterly earnings announcement on Monday, August, 20th 2018. View Earnings Estimates for Cleveland BioLabs.

Who are some of Cleveland BioLabs' key competitors?

Who are Cleveland BioLabs' key executives?

Cleveland BioLabs' management team includes the folowing people:
  • Dr. Yakov N. Kogan M.B.A., Ph.D., MBA, Chief Exec. Officer and Interim Principal Financial Officer (Age 45)
  • Dr. Langdon L. Miller, Pres & Chief Medical Officer (Age 64)
  • Dr. Andrei V. Gudkov, Chief Scientific Officer (Age 62)
  • Dr. Ann Lenich Hards Ph.D., Exec. VP of Regulatory Affairs
  • Dr. Andrei Purmal Ph.D., VP of Chemistry

Has Cleveland BioLabs been receiving favorable news coverage?

Headlines about CBLI stock have been trending somewhat positive on Saturday, according to Accern. The research group identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Cleveland BioLabs earned a coverage optimism score of 0.12 on Accern's scale. They also assigned headlines about the biotechnology company an impact score of 45.69 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future. View Recent Headlines for Cleveland BioLabs.

How do I buy shares of Cleveland BioLabs?

Shares of CBLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cleveland BioLabs' stock price today?

One share of CBLI stock can currently be purchased for approximately $1.85.

How big of a company is Cleveland BioLabs?

Cleveland BioLabs has a market capitalization of $24.40 million and generates $1.95 million in revenue each year. Cleveland BioLabs employs 19 workers across the globe.

How can I contact Cleveland BioLabs?

Cleveland BioLabs' mailing address is 73 HIGH STREET, BUFFALO NY, 14203. The biotechnology company can be reached via phone at 716-849-6810 or via email at [email protected]


MarketBeat Community Rating for Cleveland BioLabs (NASDAQ CBLI)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  97 (Vote Outperform)
Underperform Votes:  77 (Vote Underperform)
Total Votes:  174
MarketBeat's community ratings are surveys of what our community members think about Cleveland BioLabs and other stocks. Vote "Outperform" if you believe CBLI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBLI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/18/2018 by MarketBeat.com Staff

Featured Article: Trading Penny Stocks

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.